Effectiveness and safety of extended-release nicotinic acid for reducing serum phosphorus in hemodialysis patients

Journal of Nephrology

Volumn 25, Issue 3, 2012, Pages 354-362

  Aramwit, Pornanong ^a   Srisawadwong, Rachanon ^a   Supasyndh, Ouppatham ^b  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b PHRAMONGKUTKLAO HOSPITAL   (Thailand)

Author keywords

Extended release nicotinic acid; Hemodialysis; Hyperphosphatemia; Niacin

Indexed keywords

ALUMINUM HYDROXIDE; ATORVASTATIN; CALCIUM; CALCIUM CARBONATE; GEMFIBROZIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER ENZYME; NICOTINIC ACID; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; PLACEBO; ROSUVASTATIN; SIMVASTATIN; URIC ACID; VITAMIN D DERIVATIVE;

ADD ON THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BEDTIME DOSAGE; BURNING LIP; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HEMODIALYSIS PATIENT; HOT FLUSH; HUMAN; HYPERPHOSPHATEMIA; LIP DISEASE; MAJOR CLINICAL STUDY; MALE; MYALGIA; PAINFUL LIP; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; SIDE EFFECT; URIC ACID BLOOD LEVEL;

ADULT; AGED; ANALYSIS OF VARIANCE; CHELATING AGENTS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERPHOSPHATEMIA; MALE; MIDDLE AGED; NIACIN; PHOSPHORUS; RENAL DIALYSIS; THAILAND; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION; YOUNG ADULT;

EID: 84863323765     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000011     Document Type: Article

References (26)

1. Nolin TD, Frye RF, Matzke GR. Hepatic drug metabolism and transport in patients with kidney disease. Am J Kidney Dis. 2003;42:906-925.
2. Aramwit P, Supasyndh O, Sriboonruang T. Pharmacokinetics of single-dose rosiglitazone in chronic ambulatory peritoneal dialysis patients. J Clin Pharm Ther. 2008;33:685-690.
3. Suliman ME, Johnson RJ, García-López E, et al. J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis. 2006;48:761-771.
4. Qunibi W, Winkelmayer WC, Solomon R, et al. A randomized, double-blind, placebo-controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non-dialysis-dependent chronic kidney disease. BMC Nephrol. 2011;12:9.
5. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31:607-617.
6. Thomas R, Kanso A, Sedor JR. Chronic kidney disease and its complications. Prim Care. 2008;35:329-344, vii.
7. Hruska KA, Mathew S, Lund R, Qiu P, Pratt R. Hyperphosphatemia of chronic kidney disease. Kidney Int. 2008;74:148-157.
8. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA. 2007;298:786-798.
9. Berns JS. Niacin and related compounds for treating hyperphosphatemia in dialysis patients. Semin Dial. 2008;21: 203-205.
10. Cheng SC, Young DO, Huang Y, Delmez JA, Coyne DW. A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol. 2008;3:1131-1138.
11. Maccubbin D, Tipping D, Kuznetsova O, Hanlon WA, Bostom AG. Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial. Clin J Am Soc Nephrol. 2010;5:582-589.
12. Müller D, Mehling H, Otto B, et al. Niacin lowers serum phosphate and increases HDL cholesterol in dialysis patients. Clin J Am Soc Nephrol. 2007;2:1249-1254.
13. Sampathkumar K, Selvam M, Sooraj YS, Gowthaman S, Ajeshkumar RN. Extended release nicotinic acid: a novel oral agent for phosphate control. Int Urol Nephrol. 2006;38:171-174.
14. Katai K, Tanaka H, Tatsumi S, et al. Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine. Nephrol Dial Transplant. 1999;14:1195-1201.
15. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug: a 50th anniversary review. J Intern Med. 2005;258:94-114.
16. Carlson LA. Niaspan, the prolonged release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug. Int J Clin Pract. 2004;58:706-713.
17. McCormack PL, Keating GM. Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia. Drugs. 2005;65:2719-2740.
18. Pieper JA. Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety. Am J Health Syst Pharm. 2003;60:S9-S14 [quiz: S25].
19. Cirillo M, Bilancio G, Marcarelli F. Ageing and changes in phosphate transport: clinical implications. J Nephrol. 2010;23(Suppl 16):S152-S157
20. Restrepo Valencia CA, Cruz J. Safety and effectiveness of nicotinic acid in the management of patients with chronic renal disease and hyperlipidemia associated to hyperphosphatemia. Nefrologia. 2008;28:61-66.
21. Reiche I, Westphal S, Martens-Lobenhoffer J, Tröger U, Luley C, Bode-Böger SM. Pharmacokinetics and dose recommendations of Niaspan® in chronic kidney disease and dialysis patients. Nephrol Dial Transplant. 2011;26:276-282.
22. Damasiewicz MJ, Toussaint ND, Polkinghorne KR. Fibroblast growth factor 23 in chronic kidney disease: new insights and clinical implications. Nephrology (Carlton). 2011;16:261-268.
23. Benet-Pagès A, Orlik P, Strom TM, Lorenz-Depiereux B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet. 2005;14:385-390.
24. Feng JQ, Ward LM, Liu S, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet. 2006;38:1310-1315.
25. Ix JH, Shlipak MG, Wassel CL, Whooley MA. Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Nephrol Dial Transplant. 2010;25: 993-997.
26. Jean G, Terrat JC, Vanel T, et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant. 2009;24:2792-2796.